CBAY – cymabay therapeutics inc. (US:NASDAQ)
Stock Stats
News
3/25
02:06 am
cbay
Neutral
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/17
02:02 am
cbay
Low
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/11
02:33 pm
cbay
Low
Investing in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gain [Yahoo! Finance]
3/11
08:30 am
cbay
Low
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer [Yahoo! Finance]
3/11
05:26 am
cbay
Low
Global Primary Biliary Cholangitis Therapeutics Market 2024-2034 - Hospital Pharmacies Lead Distribution, But Online Pharmacies to Experience Rapid Growth Amid Digital Healthcare Boom [Yahoo! Finance]
11/7/2023
04:04 pm
CBAY
-4.5%
MISS
8/10/2023
04:04 pm
CBAY
3.9%
BEAT
5/15/2023
04:04 pm
CBAY
-7.5%
MISS
2/29
09:10 am
Reiterates
Neutral
Neutral
HC Wainwright
Low
-0.3%
2/20
05:01 am
Downgrades
Outperform
Market Perform
Leerink Partners
Low
0.6%
2/14
08:03 am
Reiterates
Buy
Neutral
UBS Group AG
Medium
3.0%
2/14
07:15 am
Downgrades
Buy
Neutral
UBS
Low
0.3%
2/13
08:40 am
Reiterates
Buy
Neutral
BTIG Research
Low
-0.1%
3/22
05:10 pm
cbay
Neutral
Form 4 CymaBay Therapeutics, For: Mar 22 Filed by: Loewy Caroline M
3/22
05:06 pm
cbay
Neutral
Form 4 CymaBay Therapeutics, For: Mar 22 Filed by: McWherter Charles
3/22
05:06 pm
cbay
Neutral
Form 4 CymaBay Therapeutics, For: Mar 22 Filed by: Lefebvre Eric
3/22
05:04 pm
cbay
Neutral
Form 4 CymaBay Therapeutics, For: Mar 22 Filed by: Dorling Janet
3/22
05:03 pm
cbay
Neutral
Form 4 CymaBay Therapeutics, For: Mar 22 Filed by: Shantharam Harish
Show more
Top News Gainers
11/26 CymaBay Therapeutics Inc (NASDAQ: CBAY) was downgraded by analysts at Raymond James from a "strong-buy" rating to a "market perform" rating. 24.8%
6/11 CymaBay Therapeutics stock down 43% after NASH trial data disappoint investors [MarketWatch] 17.8%
12/12 Form SC 13D CymaBay Therapeutics, Filed by: ENGINE CAPITAL, L.P. 16.0%
3/12 Q4/2019 12/31/2019 EPS -0.430 ZacksConsensus -0.390 ActVsEst (0.040) - Miss 12.8%
12/20 CymaBay to cut 60% of workforce; shares down 8% after hours [Seeking Alpha] 10.5%
6/13 CymaBay Therapeutics Inc (NASDAQ: CBAY) had its price target lowered by analysts at Citigroup Inc from $21.00 to $12.00. They now have a "buy" rating on the stock. 9.2%
11/5 Q3/2019 9/30/2019 EPS -0.380 ZacksConsensus -0.370 ActVsEst (0.010) - Miss 9.1%
11/27 CymaBay Therapeutics Inc (NASDAQ: CBAY) was downgraded by analysts at Svb Leerink Llc from an "outperform" rating to a "market perform" rating. 8.7%
2/14 Form SC 13G/A CymaBay Therapeutics, Filed by: Foresite Capital Fund III, L.P. 8.7%
11/4 CymaBay Therapeutics Reaches Target Enrollment in the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis 8.5%
Top News Decliners
6/11 CymaBay Therapeutics Reports Topline 12-Week Data from an Ongoing Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis -39.4%
3/13 Form SC 13D/A CymaBay Therapeutics, Filed by: ENGINE CAPITAL, L.P. -12.5%
1/29 Form 8-K CymaBay Therapeutics, For: Jan 23 -12.2%
3/16 Form 10-K CymaBay Therapeutics, For: Dec 31 -7.7%
3/4 CYMABAY ALERT: Bragar Eagel & Squire, P.C. Is Investigating CymaBay Therapeutics, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm -6.0%
3/18 CymaBay Therapeutics Inc (NASDAQ: CBAY) had its price target lowered by analysts at B. Riley from $2.00 to $1.50. They now have a "neutral" rating on the stock. -6.0%
8/5 CymaBay Therapeutics Strengthens Management Team with Appointment of Janet Dorling as Chief Commercial Officer -6.0%
6/12 CymaBay Therapeutics Inc (NASDAQ: CBAY) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -5.7%
10/10 CymaBay Therapeutics Inc (NASDAQ: CBAY) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -5.5%
10/8 CymaBay Therapeutics Inc (NASDAQ: CBAY) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $5.75 price target on the stock. -5.0%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3